Company’s 36-month beta value is 1.35.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for LUCD is 22.53M, and currently, short sellers hold a 4.61% ratio of that floaft. The average trading volume of LUCD on March 06, 2025 was 544.04K shares.
LUCD) stock’s latest price update
Lucid Diagnostics Inc (NASDAQ: LUCD)’s stock price has increased by 1.48 compared to its previous closing price of 1.35. However, the company has seen a -8.67% decrease in its stock price over the last five trading sessions. prnewswire.com reported 2025-03-05 that NEW YORK, March 5, 2025 /PRNewswire/ — Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced registered direct offering of 13,939,331 shares of common stock at a purchase price of $1.10 per share. The gross proceeds to the Company from this offering are approximately $15.3 million, before deducting the approximately $0.8 million in placement agent’s fees and other offering expenses payable by the Company.
LUCD’s Market Performance
Lucid Diagnostics Inc (LUCD) has seen a -8.67% fall in stock performance for the week, with a 47.33% gain in the past month and a 39.92% surge in the past quarter. The volatility ratio for the week is 10.47%, and the volatility levels for the past 30 days are at 12.47% for LUCD. The simple moving average for the last 20 days is -0.26% for LUCD stock, with a simple moving average of 52.01% for the last 200 days.
Analysts’ Opinion of LUCD
Many brokerage firms have already submitted their reports for LUCD stocks, with Ascendiant Capital Markets repeating the rating for LUCD by listing it as a “Buy.” The predicted price for LUCD in the upcoming period, according to Ascendiant Capital Markets is $16 based on the research report published on December 27, 2021 of the previous year 2021.
Needham, on the other hand, stated in their research note that they expect to see LUCD reach a price target of $17. The rating they have provided for LUCD stocks is “Buy” according to the report published on November 08th, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to LUCD, setting the target price at $21 in the report published on November 08th of the previous year.
LUCD Trading at 29.38% from the 50-Day Moving Average
After a stumble in the market that brought LUCD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.11% of loss for the given period.
Volatility was left at 12.47%, however, over the last 30 days, the volatility rate increased by 10.47%, as shares surge +45.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +79.01% upper at present.
During the last 5 trading sessions, LUCD fell by -8.00%, which changed the moving average for the period of 200-days by +55.06% in comparison to the 20-day moving average, which settled at $1.3741. In addition, Lucid Diagnostics Inc saw 67.34% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for LUCD
Current profitability levels for the company are sitting at:
- -10.77 for the present operating margin
- -0.85 for the gross margin
The net margin for Lucid Diagnostics Inc stands at -10.7. The total capital return value is set at -5.41. Equity return is now at value -1007.83, with -160.52 for asset returns.
Based on Lucid Diagnostics Inc (LUCD), the company’s capital structure generated 0.67 points at debt to capital in total, while cash flow to debt ratio is standing at -3.39. The debt to equity ratio resting at 2.06. The interest coverage ratio of the stock is -1504.37.
Currently, EBITDA for the company is -49.75 million with net debt to EBITDA at 0.03. When we switch over and look at the enterprise to sales, we see a ratio of 19.42. The receivables turnover for the company is 107.41for trailing twelve months and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.18.
Conclusion
In a nutshell, Lucid Diagnostics Inc (LUCD) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
